Burden Fatty Liver Among Acute Ischemic Cerebral Stroke Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

97 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-10-10

Study Completion Date

2025-11-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Assess frequency of hepatic steatosis among patients in patients with Ischemic stroke without previous risk factors
2. Assess outcomes morbidity and mortality ischemic stroke in correlation with hepatic steatosis .

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Frequency of Metabolic Dysfunction Associated Fatty Liver Disease in Patients With Acute Coronary Syndromes

NCT06456970

Fatty Liver

NOT_YET_RECRUITING

Central Obesity and Hepatocellular Carcinoma

NCT03082378

Hepatocellular Carcinoma Obesity Microwave Ablation

UNKNOWN

Role of Abbreviated MRI in Follow-up of Hepatocellular Carcinoma .

NCT06168357

Hepatocellular Carcinoma

NOT_YET_RECRUITING

Hepatocellular Carcinoma in Patients With a Cirrhosis Due to an Alcoholic or a Non Alcoholic Fatty Liver Disease

NCT03307408

Hepatocellular Carcinoma

UNKNOWN

Characteristic and Survival Outcomes in Hepatocellular Carcinoma Patients: on Top of Viral Hepatitis Versus Combined Viral and Metabolic-Associated Steatotic Liver Disease

NCT06871930

Hepatocellular Carcinoma (HCC)

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Fatty liver disease, encompassing both alcoholic and non-alcoholic variants, is a growing health concern worldwide, with prevalence rates soaring in parallel with obesity and diabetes epidemics. The estimated global incidence of NAFLD alone is 47 cases per 1,000 people, with a higher rate observed in males than females. Among adults worldwide, the estimated prevalence of NAFLD is 32%, with a higher prevalence in males (40%) compared to females (26%), making it the most common liver disorder. The hazards of fatty liver disease extend beyond the liver itself .The condition is characterized by the accumulation of excess fat in liver cells, which can progress to more severe liver diseases, such as steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma.

Early assessment and diagnosis of liver steatosis are crucial for managing and mitigating the risks associated with FLD. Non-invasive methods, such as elastography combined with the Controlled Attenuation Parameter (CAP) score, have emerged as effective tools for detecting and quantifying liver fat content. These methods offer a less invasive alternative to liver biopsies, providing reliable data to guide clinical decisions.

NAFLD is characterized by a proinflammatory and proatherogenic state that causes vascular inflammation and neurodegeneration, potentially leading to both clinical and subclinical cerebrovascular disease. Increasing epidemiological evidence links NAFLD to a higher risk and greater severity of stroke, independent of other vascular risk factors.Additionally, studies suggest NAFLD is involved in subclinical cerebrovascular diseases, such as carotid atherosclerosis which is characterized by the build-up of plaques in the carotid arteries. Patients with NAFLD exhibited greater carotid atherosclerosis .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fatty Liver Acute Ischemic Cerebral Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Newly diagnosed ischemic cerebral stroke exceeding of window phase without obvious risk factors.
* patients above 18 years.
* patients below 60 years.

Exclusion Criteria

* patients have obvious risk factors including: smoking, DM , Hypertension ,renal patients , cardiovascular diseases (AF , valvular disease ,reduced systolic function ,chronic HCV ,HBV).
* patients below 18 years.
* patients above 60 years.
* patients refused to contribute to this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No